{"name":"Kyowa Kirin, Inc.","slug":"kyowa-kirin-inc","ticker":"","exchange":"","domain":"","description":"Kyowa Kirin, Inc. is a global specialty pharmaceutical company focused on the research, development, and commercialization of innovative therapies in nephrology, oncology, immunology, and neurology. The company has a diverse pipeline with several drugs in various stages of development, including active vitamin D and istradefylline.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Oral Phosphate Supplement","genericName":"Oral Phosphate Supplement","slug":"oral-phosphate-supplement","indication":"Other","status":"marketed"},{"name":"active vitamin D","genericName":"active vitamin D","slug":"active-vitamin-d","indication":"Treatment of hypocalcemia in patients with vitamin D deficiency or insufficiency","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Istradefylline (KW-6002)","genericName":"Istradefylline (KW-6002)","slug":"istradefylline-kw-6002","indication":"Parkinson's disease with motor fluctuations in patients on levodopa therapy","status":"phase_3"}]}],"pipeline":[{"name":"Istradefylline (KW-6002)","genericName":"Istradefylline (KW-6002)","slug":"istradefylline-kw-6002","phase":"phase_3","mechanism":"Istradefylline is an adenosine A2A receptor antagonist that blocks inhibitory signaling in the basal ganglia, thereby enhancing dopaminergic motor control.","indications":["Parkinson's disease with motor fluctuations in patients on levodopa therapy"],"catalyst":""},{"name":"Oral Phosphate Supplement","genericName":"Oral Phosphate Supplement","slug":"oral-phosphate-supplement","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"active vitamin D","genericName":"active vitamin D","slug":"active-vitamin-d","phase":"phase_3","mechanism":"Active vitamin D works by binding to vitamin D receptors in the body, which helps regulate calcium levels and bone health.","indications":["Treatment of hypocalcemia in patients with vitamin D deficiency or insufficiency"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOT1hTVnZreC1XUWg0Z29KdkdXazVHUmEwNFRoaG1KRHZaRFRoMzFIeUVDME5wSzRPV0EzTUMtX0N3NGljQVNmMy1lZEdfSHAwb0Ffd3dGQThwZHJmRnBXQTMtNVFrd1hNM2ZzMG0zY0FFdC1Yai0wal95MWxzVW5idHdKWGhBc01Td0NDN0Rsdm5sR1ZrZkQxMFNtWU1DWWNWVUswU2JlbFB4bURxb0Z6Yw?oc=5","date":"2026-01-07","type":"deal","source":"Bloomberg.com","summary":"Buyout Wave Seen Among Japan Drugmakers After Hisamitsu Deal - Bloomberg.com","headline":"Buyout Wave Seen Among Japan Drugmakers After Hisamitsu Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxOMEJUelhiaWlvS2t4eTB6Z2MwaXhsc1RkaUd6U2RxemhzbFRFV1lCM0J0TGFMOU05SGxnYjdDOURiQ011QTlBYjdVeGl6Rkk2Tnl5Y001SWF0RDFxSnN2ckQzOU1SQlFLbTZrRFUtVWF3Q2xZaGVrbWtCSGhPZXpqOXM4ZmdpZ1ZzeDRZZDNNNXFuVnJIcUZYZVV3ZVhZQU41b0l1OTFxS2NySlRkUEpXSUtVSHNJQkZsblZHcy05Q0xQZ3RubW1sUmMtQ2pjdw?oc=5","date":"2025-12-12","type":"pipeline","source":"BioSpectrum Asia","summary":"Japan's Kyowa Kirin names Dr Abdul Mullick as President and Chief Executive Officer - BioSpectrum Asia","headline":"Japan's Kyowa Kirin names Dr Abdul Mullick as President and Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxNN0JnQmducElJclA0MkhPZjJ2NHlyZUpKQ0FSUVgwUHZxZVp6SVNrNzFVcmpDZGxUSHhRRXNOXzF0bzAzaWJVYk5INVdnSnFpUTVMVzgxSUZkWDhQMTdEeW9OU3VaUWYwYlF6ejJLbnVnQkV1YkFJeExEUjdRYkNsQzBPcVRxcmdOSzg1RHYwMEFrWVN1ckNEX1huSUsya1ZnZ09SVXYwTWhWOEFpazJnM2RidE1DeWJSb1d1VVlXcDZmcUJQeFBXVmZyNjVBSk5oNzA5NnE4ckM0ZTI3SDNhRWJWR0dScUJRa1lCZ1RGYk56T3Y3dkhXZUZJNGxHUFliLVNwWlB6bkpKNFAtbVR2WGNfdVJzT3pVVUdsV0c0ajlsRDZFSzVWLTFqX3k2ck5nVnk3UA?oc=5","date":"2025-12-11","type":"regulatory","source":"Business Wire","summary":"Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman - Business Wire","headline":"Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPY3ZZQVFvT0Iya2xMU3lqWHM2bzVJYVBUNnhtX2M1Vnc1bTdsdnlzSTYwZlB5MDJvaU5tZWNRbFpSbzlXNmNMUHlqbnpmaGl5OXRKOHdKWGF4aGVabjVGVno0VlRDMjN2SGVmSS1pRndRRVNXLU9zNGstSUFOY2ZPWjVhWU5ZQTkzemp6S1VyYXBJaDJzcHdnRGRNZnZCR0FhTTVIcFFMSGZnczlHVm10SGljS0lKMmJsc2xxQkN6ekg?oc=5","date":"2025-11-13","type":"regulatory","source":"Reuters","summary":"US FDA approves Kura-Kyowa's blood cancer therapy - Reuters","headline":"US FDA approves Kura-Kyowa's blood cancer therapy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxPLWJwanpVMjVhTlpkcF9Sb1hQc18yUFhHbS1oRm5jNlFVOUJtb0tyS0RyMl90N3RQWFRoVlVJc0tPOE50Rmc2TllYZ05aYkh5V1c0czRmbkFnQ2RsdFJ0WnhkclVNak5yNWxmR1NqeF9STW9fbDlla3IyUjRWaUtrS1RseUlhRVpXWkZOaFRIaFd4U1hEU2pBSUNxSjB6QUNlOUtXNHZkRTFqWndTTTZxZXU1VWdwcnU5RU93aWxSdE5DNTJpbjdyZ0JscjE2N3l3bWV5bjBVUQ?oc=5","date":"2025-11-05","type":"pipeline","source":"Citeline News & Insights","summary":"How Abdul Mullick Is Leading Kyowa Kirin’s Global Transformation - Citeline News & Insights","headline":"How Abdul Mullick Is Leading Kyowa Kirin’s Global Transformation - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFAxMW1hWkRtSmZQQ0RXR3hvOGJNU1BqVWZmZGFnZFdMMTZUNHRXUG5yRmQ3TXpNcG5uQXVOd2JhWlAteWpiWWRVNG1TT3dJaExyNzQwUlRVd0FPQnR6MWlYWndSWnJadGtSVXQ0eWZTX2dHRkNBWVZSZG43VjRyLWc?oc=5","date":"2025-04-14","type":"pipeline","source":"Pharmaceutical Technology","summary":"Kyowa Kirin constructs drug manufacturing facility in Japan - Pharmaceutical Technology","headline":"Kyowa Kirin constructs drug manufacturing facility in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPMS1HMXJOQkZRSFBVaGJxcWJmQVVjM1dadlVnSjAzNTBXdW5Tei1KUFNCNUZMc0NBemFtY1VJdjNzUmlXeGpMbmw0eFJzaGx2MFRkQ2l4RElOUGl2MnBPWFhBc2JSYWRuR244SkpTWF9Tdk13NkZtNGxWWEc4cVFESWxZcElqb0hNMUxjMnQ2RlFYYmNIRTA2R0xKZ0lFOS03NGNsZ092Sk4yc0M3VU5LMExldG1oUmVFRHBBZFY2T0dsajZ1?oc=5","date":"2025-04-11","type":"pipeline","source":"Fierce Pharma","summary":"As work on massive US plant continues, Kyowa Kirin wraps up construction of $118M biologics plant in Japan - Fierce Pharma","headline":"As work on massive US plant continues, Kyowa Kirin wraps up construction of $118M biologics plant in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWHhmT3JXaFZGYU1ZeFRkT3VWeFd2U2pZTWg1RmtwbHk1NWMzcTdaQzBjUDMxQzJJemJVd19CaWdzSUNOd0Y3S2s2ci1NOEVOaTVVMS1KMVl1WU9LQUlHdmNBOVppbWp5a0hESE9XMHBCVWR1eEh0U3ZqdjkzX1FTcGV5Z3AwMXhUM3pFb0daMGZNODNDRV95d2tHc2VnTWY4UjUxbmM2ak9wMVQ4SVJNSGYzSTNsOXJpS1loZEphdjc5dmt6ZFI4RGVERkFwTndQc3F6Z092MGdLSWtON2hjUk5ITko5UQ?oc=5","date":"2024-08-01","type":"pipeline","source":"PR Newswire","summary":"Kyowa Kirin Announces a New Sustainable Business Strategy for the Asia-Pacific (APAC) Region - PR Newswire","headline":"Kyowa Kirin Announces a New Sustainable Business Strategy for the Asia-Pacific (APAC) Region","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPSXRCSm5HcmJiVzA2UmR5V1ZnT3RZZ3Rlci1hUU5uTVlVUVgxck93TUltRHJhWlZHMVRJNmNVMi1CWkhUMktoY05kZDUta3JYVVFiU3NSVGg2U0F6VEhkZjNHcF9SbGQwb2RZMHZ5R1k0WHg4V2ZILUN3NWV2cXY5ZnFZRHdJb0JyWjBsM2Rwd2tlNWdIang4?oc=5","date":"2024-06-14","type":"pipeline","source":"WRAL","summary":"Japanese pharma company to invest up to $530M in Sanford - WRAL","headline":"Japanese pharma company to invest up to $530M in Sanford","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQeTZvSWJsUXBXM01IV21VYnlkeWphWG1JdUQ0Z18tc1JjMFFTZi13NzAxVnkya1loNlVfQUpsSWx5NGVqeGdqQUxmSklick1SbGxKSzdPOTdHTDYtOHpJQjhPRHgyYnpteUx5YjFtTTk4bDB4cTk3TjFMTjltcUtCZHdualc3aVhVVTZJek1UREVYVkhsYU9qOU9CVVpWd3UwbjFvNG5kazhMZWVFazdtWUdPQ1dTVV9Ickd3c0l3bw?oc=5","date":"2024-06-14","type":"pipeline","source":"Manufacturing Dive","summary":"Kyowa Kirin will build $530M Research Triangle Park biologics facility - Manufacturing Dive","headline":"Kyowa Kirin will build $530M Research Triangle Park biologics facility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPRmVjdmhJUkh2cUlmZFF4VUhQd2FTY2NSU2VKN3lPVWFxbEhod0NnYU9Mdy1rTkd2NTJQMDhIbE5zZmtsWS1JYmpoQ0cyOGRick5ZLWp5S0FsRjNRakVGajFzY3VTSVdfUkdYd0w3R0oyeW9TdEJSUXp3RGppYTRXX0tvSDR2d0ZfLXFGMGV3d2F0eTU4ZU5RV0JXLWlHc3AydndmVWgxdVNzN2F6QTlGU2ZicklvdWExcVV5b05YLTByNGhvSTVGVDROc2c?oc=5","date":"2024-04-26","type":"pipeline","source":"Life Science Leader","summary":"Japan-Based Kyowa Kirin To Invest $200 Million For New Pharma Manufacturing Complex In Sanford - Life Science Leader","headline":"Japan-Based Kyowa Kirin To Invest $200 Million For New Pharma Manufacturing Complex In Sanford","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOcDZTWnpicHUxamo2Yi11ZXFqaURjemtfUEhUZ2R2VklBOUI0TlZvd0JzbXNtU3d1ZERIdHFQVlJfZElSd1dJOFI2bG90YUtRT3dvS1VneHhIVUk3d0w5X1FEZ2FZaXVFVnBsZGVxOWdGb3BEc1p4bzlpeHZCSHNjam9aTEhGU1p5UHhDYzRiV2o5Q01ZUE85dk5LbDdoT1ZMRjFzSjM4elNvdHBPcmpaSmNn?oc=5","date":"2022-01-18","type":"deal","source":"La Jolla Institute","summary":"La Jolla Institute renews longtime collaboration with Kyowa Kirin, Inc. - La Jolla Institute","headline":"La Jolla Institute renews longtime collaboration with Kyowa Kirin, Inc.","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}